Compositions and methods comprising KLK3 or FOLH1 antigen
AssigneesThe Trustees of the University of Pennsylvania, Advaxis, Inc.
InventorsYvonne Paterson, John Rothman, Vafa Shahabi
Life of this patent
Estimating the term…
Abstract
The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
Claims31
A method of inducing an anti-KLK3 immune response in a subject, comprising administering to said subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein said non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, said fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide) thereto, wherein said N-terminal LLO peptide enhances the immunogenicity of the fusion peptide, thereby inducing an anti-KLK3 immune response in a subject.
A method of treating a kallikrein-related peptidase 3 (KLK3)-expressing prostate cancer in a subject, the method comprising the step of administering to said subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein said non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, said fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide) thereto, wherein said N-terminal LLO peptide enhances the immunogenicity of the fusion peptide, whereby said subject mounts an immune response against said KLK3 protein-expressing prostate cancer, thereby treating a KLK3 protein-expressing prostate cancer in a subject.
A method of protecting a human subject against a kallikrein-related peptidase 3 (KLK3) protein-expressing prostate cancer, the method comprising the step of administering to said human subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein said non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, said fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide) thereto, wherein said N-terminal LLO peptide enhances the immunogenicity of the fusion peptide, whereby said subject mounts an immune response against said KLK3protein, thereby protecting a human subject against a KLK3 protein-expressing prostate cancer.
A recombinant fusion peptide comprising a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein said non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, said fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide) thereto.
Dependencies are inferred from the claim text.